Please login to the form below

Not currently logged in
Email:
Password:

Shire promotes Dr Jeff Jonas to lead regenerative medicines business

His former role leading specialty pharma R&D will be filled by Arnaud Partiot

Dr Jeff Jonas, ShireShire has promoted Dr Jess Jonas to president of its regenerative medicines business in a move that will also see him join the pharma company's leadership team.

Shire's regenerative medicines business was formed through its 2011 acquisition of Advanced BioHealing and Dr Jonas takes over from Kevin Rakin, who joined Advanced BioHealing in 2007. 

Dr Jonas said: “Shire's regenerative medicine business has so much potential; it serves a growing patient population with unmet needs and we have an excellent, differentiated product in Dermagraft, already commercialised for diabetic foot ulcers. We're exploring other possible indications for Dermagraft and we believe we can expand its use into new geographies.

“The science and technology in regenerative medicine is developing well and we see many opportunities to acquire other exciting assets to build a robust and attractive pipeline.”

Dr Jonas moved to Shire in 2008, prior to which he served as executive vice president at Isis Pharmaceuticals in charge of clinical and pre-clinical development, regulatory affairs, quality assurance and compliance.

Before this, he was chief medical officer and executive vice president at Forest Laboratories and began his career at Upjohn Laboratories, where he rose to become chief medical officer.

He most recently served as head of Shire's specialty R&D team, a role that will be filled by Arnaud Partiot, who is a qualified psychiatrist and has been a senior member of the Shire specialty pharmaceuticals team in various roles since joining the company in 2004.

Meanwhile, Kevin Rakin is stepping down as regenerative medicine president and from the Shire leadership team to pursue new career interests.

The changes come ahead of new Shire chief executive Flemming Ornskov joining the company in January. Ornskov will spend time with each of the company's businesses, beginning with Shire's specialty pharmaceuticals unit.

20th November 2012

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics